NasdaqGS:IBRXBiotechs
Will ImmunityBio's (IBRX) Surging Revenue and Lower Net Loss Shift Its Investment Narrative?
ImmunityBio, Inc. recently reported its third quarter 2025 results, highlighting revenue of US$32.06 million compared to US$6.11 million a year earlier, and a net loss of US$67.25 million compared to US$85.73 million in the prior year.
This marked surge in revenue and narrowed net loss points to operational progress after a period of significant business investments.
We'll explore how ImmunityBio's substantial revenue growth shapes its investment narrative in the wake of these...